WO2012020785A1 - 肝細胞がんの予防及び/又は治療のための医薬 - Google Patents
肝細胞がんの予防及び/又は治療のための医薬 Download PDFInfo
- Publication number
- WO2012020785A1 WO2012020785A1 PCT/JP2011/068226 JP2011068226W WO2012020785A1 WO 2012020785 A1 WO2012020785 A1 WO 2012020785A1 JP 2011068226 W JP2011068226 W JP 2011068226W WO 2012020785 A1 WO2012020785 A1 WO 2012020785A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- solvate
- hepatocellular carcinoma
- chain amino
- amino acid
- Prior art date
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 129
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 128
- 230000002265 prevention Effects 0.000 title claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 135
- 239000012453 solvate Substances 0.000 claims abstract description 115
- UUBHZHZSIKRVIV-KCXSXWJSSA-N (2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O UUBHZHZSIKRVIV-KCXSXWJSSA-N 0.000 claims description 102
- 150000005693 branched-chain amino acids Chemical class 0.000 claims description 99
- 239000003814 drug Substances 0.000 claims description 92
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 39
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 39
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 37
- 229960000310 isoleucine Drugs 0.000 claims description 37
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 35
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 35
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 35
- 239000004474 valine Substances 0.000 claims description 35
- 208000006454 hepatitis Diseases 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 31
- 231100000283 hepatitis Toxicity 0.000 claims description 31
- 229950010307 peretinoin Drugs 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 28
- 230000001629 suppression Effects 0.000 claims description 22
- 241000711549 Hepacivirus C Species 0.000 claims description 18
- 241000700721 Hepatitis B virus Species 0.000 claims description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 15
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 14
- 210000003494 hepatocyte Anatomy 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000002015 acyclic group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 19
- 150000004492 retinoid derivatives Chemical class 0.000 abstract description 6
- -1 cyclic retinoid Chemical class 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 229960003136 leucine Drugs 0.000 description 31
- 229960004295 valine Drugs 0.000 description 31
- 239000000203 mixture Substances 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
- 239000004473 Threonine Substances 0.000 description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 235000008521 threonine Nutrition 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 229960003121 arginine Drugs 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 229960003589 arginine hydrochloride Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 229960005337 lysine hydrochloride Drugs 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 235000004400 serine Nutrition 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229960002433 cysteine Drugs 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 210000002767 hepatic artery Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical class O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- SZNLKILVMCHHSD-OZFNKYQOSA-N (2E,6E,10E)-geranylgeranic acid Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\C(O)=O SZNLKILVMCHHSD-OZFNKYQOSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 238000012752 Hepatectomy Methods 0.000 description 2
- 208000003623 Hypoalbuminemia Diseases 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LKLFDSRDWOXLRH-OZFNKYQOSA-N (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10-trienoic acid Chemical compound CC(C)CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\C(O)=O LKLFDSRDWOXLRH-OZFNKYQOSA-N 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- XDRMXUXEFMOTSX-XFECMQBJSA-N 2-[(2E,4E)-3,7,11-trimethyldodeca-2,4-dienoyl]oxyacetic acid Chemical compound C(COC(=O)\C=C(/C)\C=C\CC(C)CCCC(C)C)(=O)O XDRMXUXEFMOTSX-XFECMQBJSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000010108 arterial embolization Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N baicalein Chemical compound C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229940057216 branchamin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- YZBNXQLCEJJXSC-UHFFFAOYSA-N miliacin Chemical compound C12CCC3C4=CC(C)(C)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(OC)C1(C)C YZBNXQLCEJJXSC-UHFFFAOYSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 229960003296 pitavastatin calcium Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940040850 prosol Drugs 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000008485 shosaiko-to Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 1
- 229960000487 sorafenib tosylate Drugs 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a medicament for the prevention and / or treatment of hepatocellular carcinoma.
- HBV hepatitis B virus
- HCV hepatitis C virus
- Non-alcoholic steatohepatitis (hereinafter sometimes referred to as “NASH” in the present specification) is a hepatitis caused by the accumulation of fat in the liver, and is associated with fatty liver. Oxidative stress, insulin resistance, inflammatory cytokines, etc. cause transition from fatty liver and deterioration of disease state. In recent years, there is a concern that an increase in metabolic syndrome (visceral fat syndrome) will increase the number of patients who develop NASH and subsequent transition to fibrosis of liver tissue, cirrhosis, and hepatocellular carcinoma. Together with hepatitis, it is important as a disease involved in the development of hepatocellular carcinoma.
- NASH Non-alcoholic steatohepatitis
- Treatment of hepatocellular carcinoma includes surgical therapies such as hepatectomy and liver transplantation, percutaneous ethanol injection therapy, medical local therapy such as radiofrequency thermal coagulation therapy or percutaneous microwave coagulation therapy, Examples include catheter therapy such as catheter arterial embolization or hepatic arterial infusion reservoir therapy, or chemotherapy such as molecular targeted drugs.
- surgical therapies such as hepatectomy and liver transplantation, percutaneous ethanol injection therapy, medical local therapy such as radiofrequency thermal coagulation therapy or percutaneous microwave coagulation therapy
- catheter therapy such as catheter arterial embolization or hepatic arterial infusion reservoir therapy
- chemotherapy such as molecular targeted drugs.
- the frequency of recurrence of hepatocellular carcinoma is high, and intra-hepatic recurrence (secondary carcinogenesis) is observed in 28.8% within 2 years from diagnosis (Non-patent Document 1).
- repeated recurrences which ultimately led to many deaths.
- sorafenib (trade name Nexabar (registered trademark)
- Nexabar registered trademark
- This drug is used only as systemic chemotherapy for unresectable hepatocellular carcinoma and has been reported to cause various serious side effects.
- the efficacy and safety of this drug in surgical treatment for hepatocellular carcinoma or adjuvant chemotherapy after internal topical medical treatment has not been established.
- Surgical treatment for hepatocellular carcinoma or internal medicine An effective and safe drug that can be used after local topical therapy has been highly desired.
- Branched-chain amino acids are used to improve encephalopathy during chronic liver injury and to improve hypoalbuminemia in patients with decompensated cirrhosis who exhibit hypoalbuminemia despite adequate food intake. ing.
- a drug containing three types of branched chain amino acids, isoleucine, leucine, and valine has an inhibitory effect on the occurrence and progression of hepatocellular carcinoma in patients with cirrhosis caused by HCV.
- this report is limited to male patients aged 25 to 75 years, and there is no description regarding effects on female patients and male patients other than the target age.
- Patent Document 1 there is no description or suggestion that these drugs are effective in suppressing recurrence after radical treatment of hepatocellular carcinoma.
- Patent Document 3 there is a report that the drug containing the branched chain amino acid has no effect on the suppression of recurrence after curative treatment for hepatocellular carcinoma from the viewpoint of either the cumulative cancer recurrence rate or the survival rate (non-patent) Reference 3) suggests that suppression of recurrence after hepatocellular carcinoma treatment is extremely difficult compared to suppression of occurrence and progression of hepatocellular carcinoma.
- An object of the present invention is to provide a medicament useful for the prevention and / or treatment of hepatocellular carcinoma.
- the present inventors have a remarkable effect of suppressing recurrence after treatment of hepatocellular carcinoma by using acyclic retinoids such as peretinoin and branched chain amino acids in combination.
- acyclic retinoids such as peretinoin and branched chain amino acids in combination.
- the present inventors have found that a combination of an acyclic retinoid and a branched chain amino acid is useful as a medicament for the prevention and / or treatment of hepatocellular carcinoma, and completed the present invention.
- hepatocellular carcinoma comprising a combination of an acyclic retinoid or a salt thereof or a solvate thereof and a branched chain amino acid or a salt thereof or a solvate thereof.
- a medicament is provided.
- a medicament for the prevention and / or treatment of hepatocellular carcinoma comprising a combination of an acyclic retinoid or a salt thereof or a solvate thereof and a branched chain amino acid or a salt thereof or a solvate thereof.
- the branched chain amino acid comprises a combination of isoleucine, leucine and valine.
- [4] The medicament according to any one of [1] to [3], wherein the prevention and / or treatment of hepatocellular carcinoma is suppression of recurrence after hepatocellular carcinoma treatment.
- [5] The medicament according to any one of [1] to [4], wherein the hepatocellular carcinoma is a hepatocyte cancer caused by hepatitis virus or non-alcoholic steatohepatitis.
- the hepatitis virus is hepatitis C virus or hepatitis B virus.
- a medicament for the prevention and / or treatment of hepatocellular carcinoma comprising an acyclic retinoid or a salt thereof or a solvate thereof; (2) Instructions that instruct the administration of the medicament in combination with a branched chain amino acid or a salt thereof or a solvate thereof;
- the medicament according to [9] above which is in the form of a kit comprising [11] A branched chain amino acid or a salt thereof or a solvate thereof for administration in combination with an acyclic retinoid or a salt thereof or a solvate thereof for the purpose of preventing and / or treating hepatocellular carcinoma. Contains medicines.
- [12] The following (1) and (2); (1) A medicament for the prevention and / or treatment of hepatocellular carcinoma, comprising a branched chain amino acid or a salt thereof or a solvate thereof; (2) Instructions that instruct the administration of the medicament in combination with an acyclic retinoid or a salt thereof or a solvate thereof;
- An effective amount of an acyclic retinoid or a salt thereof or a solvate thereof and an effective amount of a branched chain amino acid or a salt thereof or a solvate thereof may be simultaneously or varied for a patient in need thereof.
- the acyclic retinoid is peretinoin.
- the branched chain amino acid comprises a combination of isoleucine, leucine and valine.
- Acyclic retinoids or salts thereof, or solvates thereof, and branched chain amino acids, salts thereof, or solvates thereof for the manufacture of a medicament for the prevention and / or treatment of hepatocellular carcinoma Use of combinations.
- the branched chain amino acid comprises a combination of isoleucine, leucine and valine.
- the prevention and / or treatment of hepatocellular carcinoma is suppression of recurrence after hepatocellular carcinoma treatment.
- hepatocellular carcinoma is a hepatocyte cancer caused by hepatitis virus or non-alcoholic steatohepatitis.
- the hepatitis virus is hepatitis C virus or hepatitis B virus.
- An acyclic retinoid or a salt thereof or a solvate thereof for administration in combination with a branched chain amino acid or a salt thereof or a solvate thereof for the purpose of preventing and / or treating hepatocellular carcinoma [31] The acyclic retinoid or a salt thereof or a solvate thereof according to the above [30], wherein the acyclic retinoid is peretinoin. [32] The acyclic retinoid or a salt thereof, or a solvate thereof according to the above [30] or [31], wherein the branched chain amino acid comprises a combination of isoleucine, leucine and valine.
- acyclic retinoid or salt thereof according to any one of [30] to [32] above, wherein the prevention and / or treatment of hepatocellular carcinoma is suppression of recurrence after hepatocellular carcinoma treatment Or a solvate thereof.
- an excellent medicament for the prevention and / or treatment of hepatocellular carcinoma can be provided.
- the medicament of the present invention has a remarkable effect of reducing the recurrence rate of hepatocellular carcinoma with a poor prognosis because it has a remarkable effect of suppressing recurrence after hepatocellular carcinoma treatment.
- One aspect of the present invention is the prevention and / or prevention of hepatocellular carcinoma comprising, as one embodiment, a combination of an acyclic retinoid or a salt thereof or a solvate thereof and a branched chain amino acid or a salt thereof or a solvate thereof.
- a medicament for treatment hereinafter, the medicament of this embodiment may be referred to as “the combined medicament of the present invention”. That is, the combination medicament of the present invention is a medicament for the prevention and / or treatment of hepatocellular carcinoma, and comprises an acyclic retinoid or a salt thereof or a solvate thereof, a branched chain amino acid or a salt thereof or the like. Can be administered simultaneously or at different times.
- Retinoid is vitamin A (retinol) and its related compounds, and has actions such as morphogenesis, cell differentiation and growth control in vivo.
- Retinoids are classified into cyclic retinoids and acyclic retinoids according to structural characteristics (retinoids and carotenoids, 14-20 (1997), Nanzan-do).
- Examples of the cyclic retinoid include retinal, all-trans retinoic acid (tretinoin), 9-cis retinoic acid (aritretinoin), 13-cis retinoic acid (isotretinoin) and the like.
- a retinoid including a synthetic compound that exhibits binding affinity to a retinoic acid receptor.
- acyclic retinoid means one having no ring structure in the molecule among the above-mentioned broadly defined retinoids.
- Specific examples of the acyclic retinoid include geranylgeranoic acid, peretinoin, 2,3-dihydrogeranylgeranoic acid, 4,5-didehydro-10,11-dihydrogeranylgeranoic acid, 8,9-tetradehydrogeranylgeranoic acid, 4,5-didehydro-10,11,14,15-tetrahydrogeranylgeranoic acid, 14,15-dihydrogeranylgeranoic acid, methotreic acid, hydroprenoic acid, phytanic acid These can be used, and one or more of these can be used in combination.
- geranylgeranoic acid one of the acyclic retinoids, is an ingredient in medicinal herbs that increases ceramide levels of membrane lipids and causes apoptosis of liver cancer cells, and is expected as a prophylactic and therapeutic drug for cancer. It has been reported that it can be done (J. Lipid Res., 45 1092-1103 (2004)).
- acyclic retinoid salts may be used.
- an inorganic acid for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.
- an organic acid for example, Formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid Etc.
- acid addition salts for example, when an acyclic retinoid is treated as a basic compound, an inorganic acid (for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.) or an organic acid (for example, Formic acid, acetic acid
- an acyclic retinoid When treating an acyclic retinoid as an acidic compound, inorganic salts (for example, sodium salt, potassium salt, lithium salt, barium salt, calcium salt, magnesium salt, etc.) and organic salts (for example, pyridinium salt, picolinium salt, triethyl) Ammonium salt).
- an acyclic retinoid or a solvate thereof may be used.
- a physiologically acceptable organic solvent such as ethanol, acetone, ethyl acetate, hexane and the like can be used in addition to water, but the solvent is not limited thereto.
- Acyclic retinoids or salts thereof or solvates thereof, particularly the above-mentioned compounds are all known compounds and can be produced by a known method.
- peretinoin can be produced by the method described in JP-A-56-140949.
- a commercially available acyclic retinoid may be used.
- acyclic retinoid or a salt thereof or a solvate thereof is preferably peretinoin or a salt thereof or a solvate thereof, and particularly preferably peretinoin.
- examples of the “branched chain amino acid” include ⁇ -amino acids having a carbon chain branched in a side chain such as isoleucine, leucine, valine and the like. In the present invention, one or more of these are combined. Can be used.
- the branched chain amino acid may be any of D-form, L-form and a mixture thereof, but L-form is preferred in the present invention.
- a branched chain amino acid salt may be used.
- examples of such salts include inorganic acids (eg, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.) and organic acids (eg, formic acid, etc.) when handling branched chain amino acids as basic compounds. , Acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid, etc.
- inorganic acids eg, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.
- organic acids eg, formic acid, etc.
- branched chain amino acids When treating branched chain amino acids as acidic compounds, inorganic salts (eg, sodium, potassium, lithium, barium, calcium, magnesium, etc.) and organic salts (eg, pyridinium, picolinium, triethylammonium) Salt) and the like.
- inorganic salts eg, sodium, potassium, lithium, barium, calcium, magnesium, etc.
- organic salts eg, pyridinium, picolinium, triethylammonium
- a solvate of a branched chain amino acid or a salt thereof may be used.
- a physiologically acceptable organic solvent such as ethanol, acetone, ethyl acetate, hexane and the like can be used in addition to water, but the solvent is not limited thereto.
- the types of salts and solvates of various branched chain amino acids may be the same or different.
- the branched chain amino acid or a salt thereof or a solvate thereof is known and can be produced by a known method, or a commercially available branched chain amino acid may be used.
- the “branched amino acid or salt thereof or solvate thereof” preferably includes one or more branched chain amino acids selected from isoleucine, leucine and valine or salts thereof or solvates thereof, More preferred are those containing a combination of three kinds of branched chain amino acids of isoleucine, leucine and valine or a salt thereof, or a solvate thereof, particularly those containing a combination of three kinds of branched chain amino acids of isoleucine, leucine and valine. preferable.
- the combination ratio is not particularly limited, but the isoleucine free form, leucine free form and valine
- the mass ratio of the free body is preferably 1: 0.5 to 3: 0.4 to 2, and more preferably 1: 1 to 2: 0.8 to 1.4.
- the combination of three kinds of branched chain amino acids of isoleucine, leucine and valine is 952 parts by mass of isoleucine free form as a mass ratio.
- Embodiments are particularly preferred.
- the composition can be produced by a known method as an oral administration preparation or as a parenteral administration preparation.
- composition a composition containing 952 mg of isoleucine, 1904 mg of leucine and 1144 mg of valine is particularly preferable, and it is preferable to take the composition three times per day.
- the composition can be produced not only by a known method but also by a commercially available product (for example, Aminobact (registered trademark) granule, Mylan, manufactured by Nichi-Iko Co., Ltd. containing 952 mg of isoleucine, 1904 mg of leucine and 1144 mg of valine per package. Granules with aminomylan manufactured by Pharmaceutical Co., Ltd.
- Co Cosmetic (registered trademark) with Yoshindo Co., Ltd., Granules (registered trademark) with Nippon Pharmaceutical Co., Ltd., Hepaact (registered trademark) with Toa Pharmaceutical Co., Ltd. Blended granule, Rickle (registered trademark) blended granule from Sawai Pharmaceutical Co., Ltd., Levact (registered trademark) blended granule from Ajinomoto Pharmaceutical Co., Ltd., Rivaleban (registered trademark) blended granule from Medisa Shinyaku Co., Ltd., Choseidou Pharmaceutical Co., Ltd. Leobacton (registered trademark) -containing granule sachet and the like manufactured by the company) can also be used. It is preferable to take one package of the above-mentioned commercial product three times a day.
- the combination ratio of the acyclic retinoid or a salt thereof or a solvate thereof and a branched chain amino acid or a salt thereof or a solvate thereof is not particularly limited, and desired prevention and / or treatment of hepatocellular carcinoma.
- the acyclic retinoid is peretinoin
- the branched chain amino acids are isoleucine, leucine, valine, three types of branched chain amino acids or salts thereof, or a solvate thereof.
- the total amount of isoleucine free form, leucine free form and valine free form is preferably in the range of 1 to 5000 parts by weight with respect to 1 part by weight of the free form of peretinoin.
- the range is more preferably 200 parts by mass, and particularly preferably 10 to 100 parts by mass.
- prevention and / or treatment of hepatocellular carcinoma refers to prevention of development of hepatocellular carcinoma, suppression of progression of hepatocellular carcinoma, treatment of hepatocellular carcinoma, and treatment of hepatocellular carcinoma. It is a concept encompassing the suppression of recurrence of
- the medicament of the present invention can be suitably used as a medicament for suppressing recurrence after treatment for hepatocellular carcinoma, particularly for suppressing recurrence after radical cure of hepatocellular carcinoma.
- hepatocellular carcinoma in “suppression of recurrence after hepatocellular carcinoma treatment”
- surgical treatment such as hepatectomy, complete liver transplantation or partial transplantation
- transcutaneous ethanol injection Percutaneous local therapies such as therapy (PEIT), percutaneous microwave coagulation therapy (PMCT), radiofrequency heat coagulation therapy (RFA); hepatic artery chemotherapy (TAI); gelatin sponge, porous gelatin granules, embossed spheres (Embosephere: Trisacryl / gelatin spherical particles), supersorbent polymer microspheres (SAP-MS), HepaSphere, Embozene (special fluorine-coated acrylic hydrogel), hepatic artery embolization that embolizes the artery using embolizing substances such as polyvinyl alcohol Therapy (TAE); epirubicin Performed using the above-mentioned embolizing substance after lipidodization using an anticancer agent such as acid salt, cis
- PIT percutaneous microwave
- the medicament of the present invention can be administered before, after or simultaneously with the method for preventing / treating hepatocellular carcinoma.
- the method for treating hepatocellular carcinoma is not particularly limited, and the above method can be applied, or two or more can be combined.
- surgical treatment or medical local therapy is preferred.
- the background of hepatocellular carcinoma in the present invention is not particularly limited, and examples include chronic hepatitis or cirrhosis (viral, alcoholic, fatty liver, nonalcoholic), and the present invention is preferably hepatitis virus.
- hepatocellular carcinoma caused by non-alcoholic steatohepatitis more preferably hepatocellular carcinoma caused by hepatitis virus (preferably hepatitis virus positive hepatocellular carcinoma), more preferably hepatitis B virus and C Hepatoma caused by one or more viruses selected from hepatitis B virus (preferably hepatocellular carcinoma positive for one or more viruses selected from hepatitis B virus and hepatitis C virus), particularly preferably Can be applied to hepatocellular carcinoma caused by hepatitis C virus (preferably hepatitis C virus-positive hepatocellular carcinoma).
- hepatitis virus preferably hepatitis virus positive hepatocellular carcinoma
- Hepatitis B virus and C Hepatoma caused by one or more viruses selected from hepatitis B virus (preferably hepatocellular carcinoma positive for one or more viruses selected from hepatitis B virus and hepatitis C virus)
- hepatitis C virus preferably hepatit
- the medicament of the present invention has an excellent relapse-suppressing effect on patients after treatment for hepatocellular carcinoma caused by hepatitis viruses such as hepatitis C virus, and the prognosis is It became clear that it improved. Therefore, the medicament of the present invention can be particularly suitably used as a medicament for suppressing recurrence after treatment of hepatocellular carcinoma caused by hepatitis viruses such as hepatitis C virus. In addition, since the medicament of the present invention can suppress recurrence after hepatocellular carcinoma treatment, re-invasion in retreatment of recurrent liver cancer can be avoided, and the medicament of the present invention can be used after hepatocellular carcinoma treatment. It can be suitably used as a medicament for the suppression of recurrence.
- an unbranched chain amino acid or a salt thereof or a salt thereof in addition to an acyclic retinoid or a salt thereof or a solvate thereof, and a branched chain amino acid or a salt thereof or a solvate thereof, “an unbranched chain amino acid or a salt thereof or a salt thereof A “solvate” may be administered in combination.
- examples of the “unbranched amino acid” include glycine, alanine, serine, threonine, aspartic acid, glutamic acid, lysine, arginine, cysteine, cystine, methionine, phenylalanine, tyrosine, tryptophan, histidine, proline and the like.
- Examples include amino acids other than “branched chain amino acids”, and one or more of these can be combined.
- glycine, alanine, serine, threonine, lysine, arginine, methionine, phenylalanine, tryptophan, histidine, and proline are preferable as unbranched amino acids in the present invention.
- the non-branched amino acid may be any of D-form, L-form and a mixture thereof, but L-form is preferred.
- a salt of an unbranched amino acid may be used, and as the salt, a salt similar to a branched chain amino acid can be used.
- the types of salts and solvates of the various unbranched amino acids may be the same or different.
- unbranched amino acids or salts thereof or solvates thereof are known and can be produced by a known method, or commercially available unbranched amino acids may be used.
- compositions containing these solvates may be used.
- Specific examples of the composition include the following (i) to (iii).
- the said composition can be manufactured by a well-known method as an oral administration formulation and a parenteral administration formulation, a commercial item can also be used.
- a commercial item can also be used.
- injectable products such as morihepamine (registered trademark) intravenous infusion manufactured by the company can also be used.
- the aminolevan is preferably intravenously administered 500 to 1000 ml at a time
- Terfis is preferably intravenously injected 500 to 1000 ml at a time
- Hikearliestvan is intravenously injected 500 to 1000 ml at a time.
- morihepamine is intravenously administered as 500 ml at a time.
- composition can be produced by a known method as a preparation for oral administration or as a preparation for parenteral administration.
- composition can be produced by a known method as a preparation for oral administration or as a preparation for parenteral administration.
- composition containing a branched amino acid includes, for example, Aminosyn, BAXTER HEALTHCARE Branchamin, BAXTER HEALTHCARE Hepatasol, HOSPIRA Novasle, BAXTER HEALTHALE TEX, Prosol, manufactured by HOSPIRA However, it is not limited to these.
- the form of the pharmaceutical combination of the present invention is not particularly limited, and specific examples include the following forms (I) and (II).
- each preparation may be administered at the same time, or may be administered separately at an appropriate time interval, and desired prevention and / or treatment of hepatocellular carcinoma.
- Appropriate dosing schedules can be employed so that effects are achieved.
- a preparation containing an acyclic retinoid or a salt thereof or a solvate thereof and a preparation containing a branched chain amino acid or a salt thereof or a solvate thereof both preparations are simply used. It can also be provided as a kit preparation of a combination included in one package.
- the administration route of the medicament of the present invention is not particularly limited, and may be either oral administration or parenteral administration.
- the preparation for oral administration include tablets, capsules, granules, powders, syrups and the like.
- the parenteral preparation include injections, suppositories, inhalants, transdermal absorption agents, external preparations for skin, eye drops, nasal drops and the like.
- the preferred dosage form is an oral dosage form, and tablets, capsules, granules, powders, syrups and the like are particularly preferred.
- Oral administration preparations and parenteral administration preparations can be produced using known preparation additives, for example, based on known methods described in the 15th revised Japanese Pharmacopoeia General Rules for Preparations.
- the dose of the medicament of the present invention is not particularly limited, and the dose can be appropriately increased or decreased depending on various conditions such as the patient's age, weight, symptoms, dosage form, number of administrations, etc.
- peretinoin and the branched chain amino acid contains a combination of isoleucine, leucine, and valine, for example, for adults, 10 mg to 10 g, preferably 100 mg to 5 g, more preferably 300 mg per day with peretinoin as a free form It is preferable to administer ⁇ 1 g, particularly preferably 500 mg to 900 mg.
- the branched chain amino acid is 1 g to 50 g, preferably 5 g to 1 g per day in terms of the total mass of isoleucine free form, leucine free form and valine free form. It is preferable to administer 35 g, more preferably 10 g to 30 g.
- the above dose may be administered once a day, or may be administered in multiple doses.
- the present invention provides an acyclic retinoid or a salt thereof for administration in combination with a branched chain amino acid or a salt thereof or a solvate thereof for the purpose of preventing and / or treating hepatocellular carcinoma.
- the present invention provides a medicine containing a salt or a solvate thereof.
- the medicament of this aspect contains an acyclic retinoid or a salt thereof or a solvate thereof as a component, and a branched chain amino acid or a salt thereof or a salt thereof for the purpose of preventing and / or treating hepatocellular carcinoma. It is administered simultaneously with the solvate or at different times.
- kits for the prevention and / or treatment of hepatocellular carcinoma for example, a kit for the prevention and / or treatment of hepatocellular carcinoma, the following (1) and (2); (1) A medicament for the prevention and / or treatment of hepatocellular carcinoma, comprising an acyclic retinoid or a salt thereof or a solvate thereof; (2) Instructions that instruct the administration of the medicament in combination with a branched chain amino acid or a salt thereof or a solvate thereof; The kit containing is included. Specific examples of such instructions include so-called written documents (attached documents) in which explanatory matters relating to indications, effects, dosages, and dosages are described. In addition, the meaning of each word in the said aspect, the usage-amount of each component, the matter for formulation, etc. are the same as the above.
- the present invention provides, as another aspect, a branched chain amino acid or a salt thereof for administration in combination with an acyclic retinoid or a salt thereof or a solvate thereof for the purpose of preventing and / or treating hepatocellular carcinoma.
- the present invention provides a medicine containing a salt or a solvate thereof.
- the medicament of this aspect contains a branched chain amino acid or a salt thereof or a solvate thereof as a component, and for the purpose of preventing and / or treating hepatocellular carcinoma, an acyclic retinoid or a salt thereof or a salt thereof It is administered simultaneously with the solvate or at different times.
- kits for the prevention and / or treatment of hepatocellular carcinoma for example, a kit for the prevention and / or treatment of hepatocellular carcinoma, the following (1) and (2); (1) A medicament for the prevention and / or treatment of hepatocellular carcinoma, comprising a branched chain amino acid or a salt thereof or a solvate thereof; (2) Instructions that instruct the administration of the medicament in combination with an acyclic retinoid or a salt thereof or a solvate thereof; The kit containing is included. Specific examples of such instructions include so-called written documents (attached documents) in which explanatory matters relating to indications, effects, dosages, and dosages are described. In addition, the meaning of each word in the said aspect, the usage-amount of each component, the matter for formulation, etc. are the same as the above.
- Example 1 A commercially available preparation containing a combination of peretinoin produced by a known method as an acyclic retinoid and a combination of isoleucine, leucine and valine as branched chain amino acids was used.
- the Perechinoin is an expression retinoid administered in combination with the branched-chain amino acids.
- peretinoin was orally administered after meals every day for 96 weeks after the start of the test in two daily doses. Confirmation of complete cure and confirmation of recurrence of hepatocellular carcinoma were determined by performing dynamic-CT every 12 weeks after the start of the study, and the combined effect on the cumulative relapse-free rate was evaluated by the log rank test.
- Table 1 shows 50% recurrence-free period (a period until 50% of subjects relapse hepatocellular carcinoma) and 75% recurrence-free period (a period until 25% of subjects relapse with hepatocellular carcinoma). Shown in
- the medicament of the present invention has industrial applicability since it can be used as a medicament for the prevention and / or treatment of hepatocellular carcinoma.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
日本国で発生する肝細胞がんの主な原因としては、90%以上はB型肝炎ウイルス(HBV:以下、本明細書において「HBV」と記載する場合がある。)又はC型肝炎ウイルス(HCV:以下、本明細書において「HCV」と記載する場合がある。)の持続感染(慢性肝炎)によるものといわれており、ウイルス性肝炎は肝細胞がんの発生に関与する疾患として極めて重要である。また、非アルコール性脂肪性肝炎(Non-alcoholic steatohepatitis:以下、本明細書において、「NASH」と記載することがある。)は、肝臓に脂肪が蓄積することで起こる肝炎であり、脂肪肝に対する酸化ストレス、インスリン抵抗性、炎症性サイトカインなどによって、脂肪肝からの移行や病態の悪化がもたらされる。近年、メタボリックシンドローム(内臓脂肪症候群)の増加により、NASHの発症とそれに続く肝組織の線維化、肝硬変、肝細胞がんへと移行する患者が増加することが懸念されており、NASHはウイルス性肝炎とともに、肝細胞がんの発生に関与する疾患として重要である。
すなわち、本発明により、非環式レチノイド若しくはその塩又はそれらの溶媒和物、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を組み合わせてなる肝細胞がんの予防及び/又は治療のための医薬が提供される。
[1] 非環式レチノイド若しくはその塩又はそれらの溶媒和物、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を組み合わせてなる、肝細胞がんの予防及び/又は治療のための医薬。
[2] 非環式レチノイドがペレチノインである前記[1]に記載の医薬。
[3] 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、前記[1]又は[2]に記載の医薬。
[4] 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、前記[1]~[3]のいずれか1項記載の医薬。
[5] 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである前記[1]~[4]のいずれか1項記載の医薬。
[6] 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである前記[5]に記載の医薬。
[7] 非環式レチノイド若しくはその塩又はそれらの溶媒和物、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を共に含有する単一製剤(配合剤)の形態である前記[1]~[6]のいずれか1項記載の医薬。
[8] 非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する製剤、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する製剤の組み合わせを含むキット製剤の形態である前記[1]~[6]のいずれか1項記載の医薬。
[9] 肝細胞がんの予防及び/又は治療を目的として分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物と組み合わせて投与するための、非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する医薬。
[10] 下記(1)及び(2);
(1)非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する、肝細胞がんの予防及び/又は治療のための医薬;
(2)前記医薬を、分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物と組み合わせて投与することを指示する指示書;
を含むキットの形態である、前記[9]に記載の医薬。
[11] 肝細胞がんの予防及び/又は治療を目的として非環式レチノイド若しくはその塩又はそれらの溶媒和物と組み合わせて投与するための、分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する医薬。
[12] 下記(1)及び(2);
(1)分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する、肝細胞がんの予防及び/又は治療のための医薬;
(2)前記医薬を、非環式レチノイド若しくはその塩又はそれらの溶媒和物と組み合わせて投与することを指示する指示書;
を含むキットの形態である、前記[11]に記載の医薬。
[13] 非環式レチノイドがペレチノインである前記[9]~[12]のいずれか1項記載の医薬。
[14] 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、前記[9]~[13]のいずれか1項記載の医薬。
[15] 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、前記[9]~[14]のいずれか1項記載の医薬。
[16] 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである前記[9]~[15]のいずれか1項記載の医薬。
[17] 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである前記[16]に記載の医薬。
[19] 非環式レチノイドがペレチノインである前記[18]に記載の方法。
[20] 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、前記[18]又は[19]に記載の方法。
[21] 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、前記[18]~[20]のいずれか1項記載の方法。
[22] 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである前記[18]~[21]のいずれか1項記載の方法。
[23] 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである前記[22]に記載の方法。
[25] 非環式レチノイドがペレチノインである前記[24]に記載の使用。
[26] 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、前記[24]又は[25]に記載の使用。
[27] 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、前記[24]~[26]のいずれか1項記載の使用。
[28] 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである前記[24]~[27]のいずれか1項記載の使用。
[29] 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである前記[28]に記載の使用。
[31] 非環式レチノイドがペレチノインである前記[30]に記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
[32] 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、前記[30]又は[31]に記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
[33] 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、前記[30]~[32]のいずれか1項記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
[34] 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである前記[30]~[33]のいずれか1項記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
[35] 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである前記[34]に記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
[37] 非環式レチノイドがペレチノインである前記[36]に記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
[38] 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、前記[36]又は[37]に記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
[39] 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、前記[36]~[38]のいずれか1項記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
[40] 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである前記[36]~[39]のいずれか1項記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
[41] 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである前記[40]に記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
また、本発明においては非環式レチノイド又はその塩の溶媒和物を用いてもよい。当該溶媒和物を形成する溶媒としては、水のほか、生理学的に許容される有機溶媒、例えばエタノール、アセトン、酢酸エチル、ヘキサンなどを用いることができるが、これらに限定されるものではない。
また、複数種の非環式レチノイドを組み合わせて使用する場合においては、各種レチノイドの塩や溶媒和物の種類は同一でも異なっていてもよい。
なお、非環式レチノイド若しくはその塩又はそれらの溶媒和物、特に前記した化合物はいずれも公知の化合物であり、公知の方法により製造できる。例えば、ペレチノインは特開昭56-140949号公報に記載の方法により製造することができる。また、本発明においては、市販の非環式レチノイドを用いてもよい。
また、本発明においては分岐鎖アミノ酸又はその塩の溶媒和物を用いてもよい。当該溶媒和物を形成する溶媒としては、水のほか、生理学的に許容される有機溶媒、例えばエタノール、アセトン、酢酸エチル、ヘキサンなどを用いることができるが、これらに限定されるものではない。
また、複数種の分岐鎖アミノ酸を組み合わせて使用する場合においては、各種分岐鎖アミノ酸の塩や溶媒和物の種類は同一でも異なっていてもよい。
なお、分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物は公知であり、公知の方法により製造できるほか、市販の分岐鎖アミノ酸を用いてもよい。
当該組成物としては、イソロイシン952mg、ロイシン1904mg及びバリン1144mgを含有する組成物が特に好ましく、1日あたり当該組成物を3回服用することが好ましい。当該組成物は、公知の方法で製造できるのみならず、市販品(例えば、イソロイシン952mg、ロイシン1904mg及びバリン1144mgを1包あたりに含有する日医工株式会社製のアミノバクト(登録商標)配合顆粒、マイラン製薬株式会社製のアミノマイラン配合顆粒、株式会社陽進堂製のコベニール(登録商標)配合顆粒、日本製薬株式会社製のブラニュート(登録商標)顆粒、東亜薬品株式会社製のヘパアクト(登録商標)配合顆粒、沢井製薬株式会社製のリックル(登録商標)配合顆粒、味の素製薬株式会社製のリーバクト(登録商標)配合顆粒、メディサ新薬株式会社製のリバレバン(登録商標)配合顆粒、長生堂製薬株式会社製のレオバクトン(登録商標)配合顆粒分包等)も用いることができる。前記の市販品は、1日3回、1回1包を服用することが好ましい。
また、本発明の医薬は、肝細胞がん治療後の再発を抑制することができるので、再発肝がんの再治療における再度の侵襲を回避でき、本発明の医薬は肝細胞がん治療後の再発の抑制のための医薬として好適に使用できる。
複数種の非分岐鎖アミノ酸を組み合わせて使用する場合においては、各種非分岐鎖アミノ酸の塩や溶媒和物の種類は同一でも異なっていてもよい。なお、非分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物は公知であり、公知の方法により製造できるほか、市販の非分岐鎖アミノ酸を用いてもよい。
当該組成物としては、具体的には例えば、以下の(i)~(iii)等が挙げられる。
当該組成物は、公知の方法で、経口投与製剤として、また、非経口投与製剤として製造することができるが、市販品を用いることもできる。
本発明において好ましくは、イソロイシン0.9w/v%、ロイシン1.1w/v%、バリン0.84w/v%のほかに、トレオニン0.45w/v%、セリン0.5w/v%、プロリン0.8w/v%、システイン塩酸塩水和物0.04w/v%(システインとして0.03w/v%)、グリシン0.9w/v%、アラニン0.75w/v%、メチオニン0.1w/v%、フェニルアラニン0.1w/v%、トリプトファン0.07w/v%、リシン塩酸塩0.76w/v%(リシンとして0.61w/v%)、塩酸ヒスチジン0.32w/v%(ヒスチジンとして0.24w/v%)、アルギニン塩酸塩0.73w/v%(アルギニンとして0.6w/v%)といった非分岐鎖アミノ酸をも含有する非経口投与用組成物(非経口投与製剤)が挙げられ、株式会社大塚製薬工場製のアミノレバン(登録商標)点滴静注、テルモ株式会社製のテルフィス(登録商標)点滴静注、光製薬株式会社製のヒカリレバン(登録商標)注、味の素製薬株式会社製のモリヘパミン(登録商標)点滴静注等の注射剤の市販品を用いることもできる。前記アミノレバンは、1回500~1000mlを点滴静注することが好ましく、テルフィスは、1回500~1000mlを点滴静注することが好ましく、ヒカリレバンは、1回500~1000mlを点滴静注することが好ましい。また、モリヘパミンは、1回500mlを点滴静注することが好ましい。
当該組成物は、公知の方法で、経口投与製剤として、また、非経口投与製剤として、製造することもできるが、イソロイシン1.9225g、ロイシン2.037g、バリン1.602gのほかに、リシン塩酸塩0.2425g、トレオニン0.133g、アルギニン塩酸塩0.302g、塩酸ヒスチジン0.1875g及びトリプトファン0.0735gを、1包(50g)あたりに含有する大塚製薬株式会社製のアミノレバン(登録商標)EN配合散等の市販品も用いることができる。アミノレバンEN配合散を用いる場合は、1日3回、1回1包を服用することが好ましい。
当該組成物は、公知の方法で、経口投与製剤として、また、非経口投与製剤として、製造することもできるが、イソロイシン1730mg、ロイシン2122mg、バリン1615mgのほかに、リシン塩酸塩974mg、メチオニン117mg、フェニルアラニン117mg、トレオニン436mg、トリプトファン56mg、ヒスチジン306mg、アルギニン1647mg、アルギニン塩酸塩108mg、アラニン978mg、グリシン430mg、プロリン522mg、セリン257mgを、1包(80g)あたりに含有する味の素製薬株式会社製のヘパンED(登録商標)配合内用剤等の市販品も用いることができる。ヘパンED配合内用剤を用いる場合は、1日2回、1回1包を服用することが好ましい。
(I)非環式レチノイド若しくはその塩又はそれらの溶媒和物、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物の両成分を共に含有する単一製剤(配合剤)の形態。
(II)非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する製剤、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する製剤を別々に投与するための形態。
なお、当該(II)に係る形態の場合においては、各製剤を同時に投与するか、又は適宜の時間間隔をあけて別々に投与してもよく、所望の肝細胞がんの予防及び/又は治療効果が達成されるように、適切な投与計画を採用することが可能である。非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する製剤、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する製剤を別々に投与するための形態においては、両製剤を単一包装中に含む組み合わせのキット製剤として提供することもできる。
経口投与製剤、非経口投与製剤は、公知の製剤添加物を用いて、例えば、第15改正日本薬局方 製剤総則等に記載の公知の方法に基づいて製造することができる。
(1)非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する、肝細胞がんの予防及び/又は治療のための医薬;
(2)前記医薬を、分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物と組み合わせて投与することを指示する指示書;
を含むキットが挙げられる。当該指示書としては、具体的には、効能・効果や用法・用量などに関する説明事項を記載したいわゆる能書(添付文書)などが挙げられる。
なお、当該態様における各文言の意義、各成分の使用量、製剤化のための事項等は前記と同様である。
(1)分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する、肝細胞がんの予防及び/又は治療のための医薬;
(2)前記医薬を、非環式レチノイド若しくはその塩又はそれらの溶媒和物と組み合わせて投与することを指示する指示書;
を含むキットが挙げられる。当該指示書としては、具体的には、効能・効果や用法・用量などに関する説明事項を記載したいわゆる能書(添付文書)などが挙げられる。
なお、当該態様における各文言の意義、各成分の使用量、製剤化のための事項等は前記と同様である。
[使用薬物]
非環式レチノイドとしては公知の方法で製造したペレチノインを、分岐鎖アミノ酸としてはイソロイシン、ロイシン及びバリンの組み合わせを含む市販の製剤を用いた。
[方法]
HCV陽性、初発または初回再発の肝細胞がんに対して根治治療(外科的治療法又は内科的局所療法)が施され、Child-PughグレードがA又はBであり、投与前の背景に統計学的有意差がなかった被験者46名(年齢は49歳~80歳)に対し、分岐鎖アミノ酸を含有する製剤としてアミノレバン(登録商標)EN配合散、若しくはリーバクト(登録商標)配合顆粒の所定の用量(前者は1日150g(当該1日量中、L-イソロイシンを5.7675g、L-ロイシンを6.111g、L-バリンを4.806g含有)、後者は1日12.45g(当該1日量中、L-イソロイシンを2.856g、L-ロイシンを5.712g、L-バリンを3.432g含有))を試験期間中投与するとともに、被験者を以下の群に分け、非環式レチノイドであるペレチノインを前記分岐鎖アミノ酸と併用して投与した。
1:ペレチノイン600mg(1日投与量、以下同じ)併用群:18名(男性11名・女性7名)
2:ペレチノイン300mg併用群:15名(男性9名・女性6名)
3:分岐鎖アミノ酸単独投与群:13名(男性8名・女性5名)
なお、ペレチノインは1日投与量を2回に分けて試験開始後96週間の間毎日、食後経口投与した。
根治確認ならびに肝細胞がんの再発確認は、試験開始後12週ごとにダイナミック-CTを実施することによって判定し、その累積無再発率に対する併用効果をログランク検定により評価した。
結果を図1に示す。また、50%無再発期間(50%の被験者が肝細胞がんを再発するまでの期間)及び75%無再発期間(25%の被験者が肝細胞がんを再発するまでの期間)を表1に示す。
また、表1に示すとおり、75%無再発期間を分岐鎖アミノ酸単独投与群と比べると、600mg併用群では517日、300mg併用群で227日延長された。50%無再発期間の比較においては、ペレチノインと分岐鎖アミノ酸との併用は、分岐鎖アミノ酸単独投与群と比べ、倍以上の期間の延長が認められた。
したがって、ペレチノインと分岐鎖アミノ酸との併用は,肝細胞がんの再発率を低下させることが明らかとなった。特に、ペレチノイン600mgと分岐鎖アミノ酸を併用すると、分岐鎖アミノ酸を単独で投与した場合と比べて、有意に累積無再発率を改善することが明らかとなった。
Claims (41)
- 非環式レチノイド若しくはその塩又はそれらの溶媒和物、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を組み合わせてなる、肝細胞がんの予防及び/又は治療のための医薬。
- 非環式レチノイドがペレチノインである請求項1に記載の医薬。
- 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、請求項1又は2に記載の医薬。
- 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、請求項1~3のいずれか1項記載の医薬。
- 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである請求項1~4のいずれか1項記載の医薬。
- 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである請求項5に記載の医薬。
- 非環式レチノイド若しくはその塩又はそれらの溶媒和物、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を共に含有する単一製剤(配合剤)の形態である請求項1~6のいずれか1項記載の医薬。
- 非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する製剤、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する製剤の組み合わせを含むキット製剤の形態である請求項1~6のいずれか1項記載の医薬。
- 肝細胞がんの予防及び/又は治療を目的として分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物と組み合わせて投与するための、非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する医薬。
- 下記(1)及び(2);
(1)非環式レチノイド若しくはその塩又はそれらの溶媒和物を含有する、肝細胞がんの予防及び/又は治療のための医薬;
(2)前記医薬を、分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物と組み合わせて投与することを指示する指示書;
を含むキットの形態である、請求項9に記載の医薬。 - 肝細胞がんの予防及び/又は治療を目的として非環式レチノイド若しくはその塩又はそれらの溶媒和物と組み合わせて投与するための、分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する医薬。
- 下記(1)及び(2);
(1)分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物を含有する、肝細胞がんの予防及び/又は治療のための医薬;
(2)前記医薬を、非環式レチノイド若しくはその塩又はそれらの溶媒和物と組み合わせて投与することを指示する指示書;
を含むキットの形態である、請求項11に記載の医薬。 - 非環式レチノイドがペレチノインである請求項9~12のいずれか1項記載の医薬。
- 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、請求項9~13のいずれか1項記載の医薬。
- 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、請求項9~14のいずれか1項記載の医薬。
- 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである請求項9~15のいずれか1項記載の医薬。
- 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである請求項16に記載の医薬。
- 非環式レチノイド若しくはその塩又はそれらの溶媒和物の有効量と、分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物の有効量とを、必要とする患者に同時に又は時間を変えて別々に投与する工程を含む、肝細胞がんの予防及び/又は治療方法。
- 非環式レチノイドがペレチノインである請求項18に記載の方法。
- 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、請求項18又は19に記載の方法。
- 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、請求項18~20のいずれか1項記載の方法。
- 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである請求項18~21のいずれか1項記載の方法。
- 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである請求項22に記載の方法。
- 肝細胞がんの予防及び/又は治療のための医薬の製造のための、非環式レチノイド若しくはその塩又はそれらの溶媒和物、及び分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物の組み合わせの使用。
- 非環式レチノイドがペレチノインである請求項24に記載の使用。
- 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、請求項24又は25に記載の使用。
- 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、請求項24~26のいずれか1項記載の使用。
- 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである請求項24~27のいずれか1項記載の使用。
- 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである請求項28に記載の使用。
- 肝細胞がんの予防及び/又は治療を目的として分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物と組み合わせて投与するための、非環式レチノイド若しくはその塩又はそれらの溶媒和物。
- 非環式レチノイドがペレチノインである請求項30に記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
- 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、請求項30又は31に記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
- 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、請求項30~32のいずれか1項記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
- 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである請求項30~33のいずれか1項記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
- 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである請求項34に記載の非環式レチノイド若しくはその塩又はそれらの溶媒和物。
- 肝細胞がんの予防及び/又は治療を目的として非環式レチノイド若しくはその塩又はそれらの溶媒和物と組み合わせて投与するための、分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
- 非環式レチノイドがペレチノインである請求項36に記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
- 分岐鎖アミノ酸が、イソロイシン、ロイシン及びバリンの組み合わせを含むものである、請求項36又は37に記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
- 肝細胞がんの予防及び/又は治療が、肝細胞がん治療後の再発の抑制である、請求項36~38のいずれか1項記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
- 肝細胞がんが肝炎ウイルス又は非アルコール性脂肪性肝炎に起因する肝細胞がんである請求項36~39のいずれか1項記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
- 肝炎ウイルスがC型肝炎ウイルス又はB型肝炎ウイルスである請求項40に記載の分岐鎖アミノ酸若しくはその塩又はそれらの溶媒和物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013105504/15A RU2574009C2 (ru) | 2010-08-11 | 2011-08-10 | Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы |
EP11816449.0A EP2604263A4 (en) | 2010-08-11 | 2011-08-10 | MEDICAMENT FOR PREVENTING AND / OR TREATING HEPATOCELLULAR CARCINOMA |
CN2011800390609A CN103068381A (zh) | 2010-08-11 | 2011-08-10 | 用于肝细胞癌的预防和/或治疗的医药 |
US13/811,927 US8853273B2 (en) | 2010-08-11 | 2011-08-10 | Medicinal agent for prevention and/or treatment of hepatocellular carcinoma |
JP2012528695A JPWO2012020785A1 (ja) | 2010-08-11 | 2011-08-10 | 肝細胞がんの予防及び/又は治療のための医薬 |
KR1020137002889A KR101891360B1 (ko) | 2010-08-11 | 2011-08-10 | 간세포암의 예방 및/또는 치료를 위한 의약 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-180071 | 2010-08-11 | ||
JP2010180071 | 2010-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012020785A1 true WO2012020785A1 (ja) | 2012-02-16 |
Family
ID=45567747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/068226 WO2012020785A1 (ja) | 2010-08-11 | 2011-08-10 | 肝細胞がんの予防及び/又は治療のための医薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8853273B2 (ja) |
EP (1) | EP2604263A4 (ja) |
JP (2) | JPWO2012020785A1 (ja) |
KR (1) | KR101891360B1 (ja) |
CN (1) | CN103068381A (ja) |
RU (1) | RU2574009C2 (ja) |
TW (1) | TWI501763B (ja) |
WO (1) | WO2012020785A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014168191A1 (ja) * | 2013-04-10 | 2014-10-16 | 公立大学法人奈良県立医科大学 | 肝細胞がんの予防及び/又は治療剤 |
JP7127817B2 (ja) | 2018-09-07 | 2022-08-30 | 国立大学法人 東京大学 | 肺高血圧治療薬 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103735523B (zh) * | 2013-12-24 | 2015-06-17 | 深圳万乐药业有限公司 | 一种培维a酸药物组合物 |
EP4218751A3 (en) | 2016-02-23 | 2024-03-06 | Cancer Research Technology Ltd | Dietary product devoid of at least two non essential amino acid |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10167960A (ja) | 1996-12-12 | 1998-06-23 | Les-Bell:Kk | 肝細胞ガン再発抑制剤 |
EP1582207A4 (en) | 2002-12-26 | 2008-03-05 | Ajinomoto Kk | HEMMER FOR OUTBREAKING AND PROGREDIENCE OF LIVER CANCER |
RU2372900C2 (ru) * | 2004-07-14 | 2009-11-20 | Адзиномото Ко., Инк. | Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с |
JP2006241140A (ja) * | 2005-02-01 | 2006-09-14 | Otsuka Pharmaceut Factory Inc | 肝疾患用栄養組成物 |
-
2011
- 2011-08-10 JP JP2012528695A patent/JPWO2012020785A1/ja active Pending
- 2011-08-10 US US13/811,927 patent/US8853273B2/en not_active Expired - Fee Related
- 2011-08-10 KR KR1020137002889A patent/KR101891360B1/ko active IP Right Grant
- 2011-08-10 TW TW100128494A patent/TWI501763B/zh not_active IP Right Cessation
- 2011-08-10 WO PCT/JP2011/068226 patent/WO2012020785A1/ja active Application Filing
- 2011-08-10 RU RU2013105504/15A patent/RU2574009C2/ru not_active IP Right Cessation
- 2011-08-10 CN CN2011800390609A patent/CN103068381A/zh active Pending
- 2011-08-10 EP EP11816449.0A patent/EP2604263A4/en not_active Withdrawn
-
2016
- 2016-04-01 JP JP2016073863A patent/JP6359583B2/ja active Active
Non-Patent Citations (5)
Title |
---|
HIROYUKI NAKANISHI ET AL.: "Kankohen Kanja ni Okeru BCAA Seizai no Yuyosei", GASTROENTEROLOGY, vol. 49, no. 2, 28 August 2009 (2009-08-28), pages 208 - 212 * |
KAZUYUKI SUZUKI: "Bunkisa Amino Acid Seizai ni yoru Kangan Chiryo-go no Saihatsu Yokusei Koka ni Kansuru Rinsho Kyodo Kenkyu", KAN HATSUGAN YOKUSEI O SHIYA NI IRETA KANKOHEN NO EIYO RYOHO NO GUIDELINE SAKUSEI O MEZASHITA SOGOTEKI KENKYU HEISEI 21 NENDO SOKATSU BUNTAN KENKYU HOKOKUSHO, March 2010 (2010-03-01), pages 37 - 64 * |
MUTO Y ET AL.: "Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 334, no. 24, 13 July 1996 (1996-07-13), pages 1561 - 1567, XP000884177 * |
See also references of EP2604263A4 * |
TSUCHIYA K ET AL.: "Oral supplementation with branched-chain amino acids improves survival and recurrence-free survival after successful treatment of hepatocellular carcinoma in patients with cirrhosis: A prospective study", HEPATOLOGY, vol. 46, no. 4, SUPPL. 1, October 2007 (2007-10-01), pages 401A - 402A, XP003031760 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014168191A1 (ja) * | 2013-04-10 | 2014-10-16 | 公立大学法人奈良県立医科大学 | 肝細胞がんの予防及び/又は治療剤 |
JP7127817B2 (ja) | 2018-09-07 | 2022-08-30 | 国立大学法人 東京大学 | 肺高血圧治療薬 |
Also Published As
Publication number | Publication date |
---|---|
TW201210587A (en) | 2012-03-16 |
JP6359583B2 (ja) | 2018-07-18 |
US20130123363A1 (en) | 2013-05-16 |
EP2604263A1 (en) | 2013-06-19 |
RU2013105504A (ru) | 2014-09-20 |
JPWO2012020785A1 (ja) | 2013-10-28 |
TWI501763B (zh) | 2015-10-01 |
JP2016121188A (ja) | 2016-07-07 |
US8853273B2 (en) | 2014-10-07 |
KR101891360B1 (ko) | 2018-08-24 |
CN103068381A (zh) | 2013-04-24 |
RU2574009C2 (ru) | 2016-01-27 |
EP2604263A4 (en) | 2014-01-22 |
KR20130096704A (ko) | 2013-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6359583B2 (ja) | 肝細胞がんの予防及び/又は治療のための医薬 | |
AU2022202814A1 (en) | Cancer therapy | |
JP2010525050A5 (ja) | ||
RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
JP6878596B2 (ja) | Fxrアゴニストの組合せ | |
KR20050089857A (ko) | 간암 발생 및 진행 억제제 | |
CA3036230A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
JP2017533972A5 (ja) | ||
RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
IL265761B1 (en) | Tralipressin compounds for oral use for the treatment of ascites | |
KR101516677B1 (ko) | 지방성 간 질환의 치료용 의약 조성물 | |
JP2009520774A (ja) | コンブレタスタチンおよび抗癌剤を含む組合せ | |
CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 | |
RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
JP5034944B2 (ja) | インターフェロン作用物質の活性増強剤 | |
CA3216699A1 (en) | Blood carnitine-increasing agent | |
WO2014168191A1 (ja) | 肝細胞がんの予防及び/又は治療剤 | |
WO2012018145A2 (ja) | Qol改善剤 | |
WO2011135743A1 (ja) | C型肝炎の予防及び/又は治療のための医薬 | |
RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
RU2018144248A (ru) | Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта | |
WO2012144619A1 (ja) | 経口投与用慢性肝疾患治療剤 | |
JP2016510738A5 (ja) | ||
JP2021161105A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180039060.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11816449 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012528695 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013500077 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011816449 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13811927 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20137002889 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013105504 Country of ref document: RU Kind code of ref document: A |